CHARACTERIZING COVID-19-RELATED RETINAL VASCULAR OCCLUSIONS: A Case Series and Review of the Literature.
Adult
Aged
Angiogenesis Inhibitors
/ therapeutic use
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
Dexamethasone
/ therapeutic use
Drug Implants
Eye Infections, Viral
/ diagnosis
Female
Fluorescein Angiography
Glucocorticoids
/ therapeutic use
Humans
Intravitreal Injections
Male
Middle Aged
Retinal Vein Occlusion
/ diagnosis
Retrospective Studies
SARS-CoV-2
/ genetics
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
/ physiology
COVID-19 Drug Treatment
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
17
12
2021
medline:
5
3
2022
entrez:
16
12
2021
Statut:
ppublish
Résumé
To describe clinical and ophthalmologic features and outcomes of patients with coronavirus disease-19 with retinal vascular occlusions. Retrospective multicenter case series and PubMed review of cases reported from March 2020 to September 2021. Outcome measures are as follows: type of occlusion, treatments, best-corrected visual acuity, and central macular thickness on optical coherence tomography. Thirty-nine patients were identified. Fifteen patients with a median age of 39 (30-67) years were included in the multicenter study. Vascular occlusions included central retinal vein occlusion (12 eyes), branch retinal vein occlusion (4 eyes), and central retinal artery occlusion (2 eyes). Three cases were bilateral. Baseline best-corrected visual acuity was 20/45 (no light perception-20/20). Baseline central macular thickness was 348.64 (±83) μm. Nine eyes received anti-vascular endothelial growth factor agents, dexamethasone intravitreal implant, or both. Final best-corrected visual acuity was 20/25 (no light perception-20/20), and central macular thickness was 273.7 ± 68 μm (follow-up of 19.6 ± 6 weeks). Among the 24 cases from the literature review, retinal vein occlusion was the predominant lesion. Clinical characteristics and outcomes were similar to those found in our series. Coronavirus disease-19-associated retinal vascular occlusions tend to occur in individuals younger than 60 years. Retinal vein occlusion is the most frequent occlusive event, and outcomes are favorable in most cases.
Identifiants
pubmed: 34914345
doi: 10.1097/IAE.0000000000003327
pii: 00006982-202203000-00008
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Drug Implants
0
Glucocorticoids
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Dexamethasone
7S5I7G3JQL
Types de publication
Case Reports
Journal Article
Multicenter Study
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-475Références
González-Gay MA, Mayo J, Castañeda S, et al. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Expert Opin Biol Ther 2020;20:717–723.
Borobia AM, Carcas AJ, Arnalich F, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med 2020;9:1733.
Voicu S, Ketfi C, Stépanian A, et al. Pathophysiological processes underlying the high prevalence of deep vein thrombosis in critically ill COVID-19 patients. Front Physiol 2020;11:608788.
Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020;69:1181–1189.
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–128.
Abdul-Kadir MA, Lim LT. Human coronaviruses: ophthalmic manifestations. BMJ Open Ophthalmol 2020;5:e000630.
Abrishami M, Emamverdian Z, Shoeibi N, et al. Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study. Can J Ophthalmol 2021;56:24–30.
Lani-Louzada R, Ramos C, Cordeiro RM, Sadun AA. Retinal changes in COVID-19 hospitalized cases. PLoS One 2020;15:e0243346.
Pereira LA, Soares LCM, Nascimento PA, et al. Retinal findings in hospitalised patients with severe COVID-19. Br J Ophthalmol 2020: bjophthalmol-2020-317576. Epub ahead of print.
Gascon P, Briantais A, Bertrand E, et al. Covid-19-associated retinopathy: a case report. Ocul Immunol Inflamm 2020;28:1293–1297.
Virgo J, Mohamed M. Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye (Lond) 2020;34:2352–2353.
Naughton A, Ong AY, Gkika T, Downes S. Bilateral paracentral acute middle maculopathy in a SARS-CoV-2-positive patient. Postgrad Med J 2021: postgradmedj-2021-140500. Epub ahead of print.
Ozsaygili C, Bayram N, Ozdemir H. Cilioretinal artery occlusion with paracentral acute middle maculopathy associated with COVID-19. Indian J Ophthalmol 2021;69:1956–1959.
Padhy SK, Dcruz RP, Kelgaonkar A. Paracentral acute middle maculopathy following SARS-CoV-2 infection: the D-dimer hypothesis. BMJ Case Rep 2021;14:e242043.
Invernizzi A, Pellegrini M, Messenio D, et al. Impending central retinal vein occlusion in a patient with coronavirus disease 2019 (COVID-19). Ocul Immunol Inflamm 2020;28:1290–1292.
Rego Lorca D, Rouco Fernandez A, Jimenez Santos M, et al. Bilateral retinal vein occlusion and diabetic retinopathy after COVID-19. Acta Ophthalmol 2021;99:e1246–e1248.
Gaba WH, Ahmed D, Al Nuaimi RK, et al. Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (COVID-19) pneumonia. Am J Case Rep 2020;21:e927691.
Yahalomi T, Pikkel J, Arnon R, Pessach Y. Central retinal vein occlusion in a young healthy COVID-19 patient: a case report. Am J Ophthalmol Case Rep 2020;20:100992.
Insausti-Garcia A, Reche-Sainz JA, Ruiz-Arranz C, et al. Papillophlebitis in a COVID-19 patient: Inflammation and hypercoagulable state. Eur J Ophthalmol 2020:1120672120947591 Epub ahead of print..
Walinjkar JA, Makhija SC, Sharma HR, et al. Central retinal vein occlusion with COVID-19 infection as the presumptive etiology. Indian J Ophthalmol 2020;68:2572–2574.
Miller CG, Kim BJ. Central retinal vein occlusion in a 46-year-old man with COVID-19: case report and review of the literature. Case Rep Ophthalmol 2021;12:646–652.
Raval N, Djougarian A, Lin J. Central retinal vein occlusion in the setting of COVID-19 infection. J Ophthalmic Inflamm Infect 2021;11:10.
Venkatesh R, Reddy NG, Agrawal S, Pereira A. COVID-19-associated central retinal vein occlusion treated with oral aspirin. BMJ Case Rep 2021:14:e242987.
Sheth JU, Narayanan R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: a novel entity. Indian J Ophthalmol 2020;68:2291–2293.
Nourinia R, Ghassempour M, Ahmadieh H, Abtahi SH. Branch retinal vein occlusion after COVID-19. J Fr Ophtalmol 2021;44:e441–e443.
Finn AP, Khurana RN, Chang LK. Hemi-retinal vein occlusion in a young patient with COVID-19. Am J Ophthalmol Case Rep 2021;22:101046.
Acharya S, Diamond M, Anwar S, et al. Unique case of central retinal artery occlusion secondary to COVID-19 disease. IDCases 2020;21:e00867.
Dumitrascu OM, Volod O, Bose S, et al. Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. J Stroke Cerebrovasc Dis 2020;29:104982.
Montesel A, Bucolo C, Mouvet V, et al. Case Report: central retinal artery occlusion in a COVID-19 patient. Front Pharmacol 2020;11:588384.
Bapaye MM, Nair AG, Bapaye CM, et al. Simultaneous bilateral central retinal artery occlusion following COVID-19 infection. Ocul Immunol Inflamm 2021;29:671–674.
Ucar F, Cetinkaya S. Central retinal artery occlusion in a patient who contracted COVID-19 and review of similar cases. BMJ Case Rep 2021;14:e244181.
Uzun A, Keles Sahin A, Bektas O. A unique case of branch retinal artery occlusion associated with a relatively mild Coronavirus Disease 2019. Ocul Immunol Inflamm 2021;29:715–718.
Kohner EM, Cappin JM. Do medical conditions have an influence on central retinal vein occlusions? Proc R Soc Med 1974;67:1052–1054.
Lee KE, Tschoe C, Coffman SA, et al. Management of acute central retinal artery occlusion, a ‟retinal stroke”: an institutional series and literature review. J Stroke Cerebrovasc Dis 2021;30:105531.
Invernizzi A, Torre A, Parrulli S, et al. Retinal findings in patients with COVID-19: results from the SERPICO-19 study. EClinicalMedicine 2020;27:100550.
Eah KS, Kim YN, Park YJ, et al. Central retinal vein occlusion in young patients: clinical characteristics and prognostic factors. Retina 2021;41:630–637.
Rahimy E, Kuehlewein L, Sadda SR, Sarraf D. Paracentral Acute Middle Maculopathy: what we knew then and what we know now. Retina 2015;35:1921–1930.
Bhavsar KV, Lin S, Rahimy E, et al. Acute macular neuroretinopathy: a comprehensive review of the literature. Surv Ophthalmol 2016;61:538–565.
Benjamin LA, Paterson RW, Moll R, et al. Antiphospholipid antibodies and neurological manifestations in acute COVID-19: a single-centre cross-sectional study. EClinicalMedicine 2021;00:101070.
Pelegrín L, Hernández-Rodríguez J, Espinosa G, et al. Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. Autoimmun Rev 2017;16:237–243.
Sim SS, Cheung CMG. Does COVID-19 infection leave a mark on the retinal vasculature? Can J Ophthalmol 2021;56:4–5.